Chronic obstructive pulmonary disease (COPD): Evaluation from clinical, immunological and bacterial pathogenesis perspectives

Journal of Microbiology

Volumn 52, Issue 3, 2014, Pages 211-226

  Hassett, Daniel J ^a,b   Borchers, Michael T ^a,b   Panos, Ralph J ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

airway infections; biofilm; Chronic obstructive pulmonary disease (COPD); innate and adaptive immunity; Pseudomonas aeruginosa; smoking

Indexed keywords

ANTIINFECTIVE AGENT;

BIOFILM; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFECT; DRUG THERAPY; GROWTH, DEVELOPMENT AND AGING; HEALTH; HUMAN; METHODOLOGY; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVIEW;

ANTI-BACTERIAL AGENTS; BIOFILMS; DRUG THERAPY; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; WORLD HEALTH;

EID: 84895083862     PISSN: 12258873     EISSN: 19763794     Source Type: Journal    
DOI: 10.1007/s12275-014-4068-2     Document Type: Review

References (165)

1. Aaron, S. D., Vandemheen, K. L., Fergusson, D., Maltais, F., Bourbeau, J., Goldstein, R., Balter, M., O'Donnell, D., McIvor, A., Sharma, S., andet al. 2007. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 146, 545-555.
2. Agaku, I., King, B., and Dube, S. R. 2012. Current Cigarette Smoking Among Adults - United States, 2011. Morbidity and Mortality Weekly Report. CDC, Dept. of Health and Human Services.
3. Agusti, A. 2007. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). Proc. Am. Thorac. Soc. 4, 522-525.
4. Agusti, A. and Soriano, J. B. 2008. COPD as a systemic disease. COPD5, 133-138.
5. Albert, R. K., Connett, J., Bailey, W. C., Casaburi, R., Cooper, J. A., Jr., Criner, G. J., Curtis, J. L., Dransfield, M. T., Han, M. K., Lazarus, S. C., andet al. 2011. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 365, 689-698.
6. Almagro, P., Salvado, M., Garcia-Vidal, C., Rodriguez-Carballeira, M., Cuchi, E., Torres, J., and Heredia, J. L. 2012. Pseudomonas aeruginosa and mortality after hospital admission for chronic obstructive pulmonary disease. Respiration84, 36-43.
7. Almirall, J., Gonzalez, C. A., Balanzo, X., and Bolibar, I. 1999. Pro portion of community-acquired pneumonia cases attributable to tobacco smoking. Chest116, 375-379.
8. Aryal, S., Diaz-Guzman, E., and Mannino, D. M. 2013. COPD and gender differences: an update. Transl. Res. 162, 208-218.
9. Barker, B. L. and Brightling, C. E. 2013. Phenotyping the heterogeneity of chronic obstructive pulmonary disease. Clin. Sci. (Lond)124, 371-387.
10. Barnes, P. J. 2011. Triple inhalers for obstructive airways disease: will they be useful? Expert. Rev. Respir. Med. 5, 297-300.
11. Barnes, P. J. and Celli, B. R. 2009. Systemic manifestations and comorbidities of COPD. Eur. Respir. J. 33, 1165-1185.
12. Barraud, N., Hassett, D. J., Hwang, S. H., Rice, S. A., Kjelleberg, S., and Webb, J. S. 2006. Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa. J. Bacteriol. 188, 7344-7353.
13. Barton, G. M. 2008. A calculated response: control of inflammation by the innate immune system. J. Clin. Invest. 118, 413-420.
14. Beasley, V., Joshi, P. V., Singanayagam, A., Molyneaux, P. L., Johnston, S. L., and Mallia, P. 2012. Lung microbiology and exacerbations in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 7, 555-569.
15. Beauchamp, M. K., Hill, K., Goldstein, R. S., Janaudis-Ferreira, T., and Brooks, D. 2009. Impairments in balance discriminate fallers from non-fallers in COPD. Respir. Med. 103, 1885-1891.
16. Beauchamp, M. K., Sibley, K. M., Lakhani, B., Romano, J., Mathur, S., Goldstein, R. S., and Brooks, D. 2012. Impairments in systems underlying control of balance in COPD. Chest141, 1496-1503.
17. Bernard, S., LeBlanc, P., Whittom, F., Carrier, G., Jobin, J., Belleau, R., and Maltais, F. 1998. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 158, 629-634.
18. Bestall, J. C., Paul, E. A., Garrod, R., Garnham, R., Jones, P. W., and Wedzicha, J. A. 1999. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax54, 581-586.
19. Borchers, M. T., Wesselkamper, S. C., Curull, V., Ramirez-Sarmiento, A., Sanchez-Font, A., Garcia-Aymerich, J., Coronell, C., Lloreta, J., Agusti, A. G., Gea, J., andet al. 2009. Sustained CTL activation by murine pulmonary epithelial cells promotes the development of COPD-like disease. J. Clin. Invest. 119, 636-649.
20. Bosken, C. H., Hards, J., Gatter, K., and Hogg, J. C. 1992. Characterization of the inflammatory reaction in the peripheral airways of cigarette smokers using immunocytochemistry. Am. Rev. Respir. Dis. 145, 911-917.
21. Bourbeau, J. 2010. Making pulmonary rehabilitation a success in COPD. Swiss Med. Wkly140, w13067.
22. Bradley, J. P., Bacharier, L. B., Bonfiglio, J., Schechtman, K. B., Strunk, R., Storch, G., and Castro, M. 2005. Severity of respiratory syncytial virus bronchiolitis is affected by cigarette smoke exposure and atopy. Pediatrics115, e7-14.
23. Bratke, K., Klug, M., Bier, A., Julius, P., Kuepper, M., Virchow, J. C., and Lommatzsch, M. 2008. Function-associated surface molecules on airway dendritic cells in cigarette smokers. Am. J. Respir. Cell. Mol. Biol. 38, 655-660.
24. Brook, I. and Frazier, E. H. 2003. Immune response to Fusobacterium nucleatum and Prevotella intermedia in the sputum of patients with acute exacerbation of chronic bronchitis. Chest124, 832-833.
25. Buist, A. S., McBurnie, M. A., Vollmer, W. M., Gillespie, S., Burney, P., Mannino, D. M., Menezes, A. M., Sullivan, S. D., Lee, T. A., Weiss, K. B., andet al. 2007. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet370, 741-750.
26. Buskin, S. E., Gale, J. L., Weiss, N. S., and Nolan, C. M. 1994. Tuberculosis risk factors in adults in King County, Washington, 1988 through 1990. Am. J. Public Health84, 1750-1756.
27. Butcher, S. J., Meshke, J. M., and Sheppard, M. S. 2004. Reductions in functional balance, coordination, and mobility measures among patients with stable chronic obstructive pulmonary disease. J. Cardiopulm. Rehabil. 24, 274-280.
28. Camp, P. G. and Goring, S. M. 2007. Gender and the diagnosis, management, and surveillance of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 4, 686-691.
29. Capehart, T. C. 2006. Tobacco Situation and Outlook Yearbook, 2007. TBS-2006. E. R. S. United States Department of Agriculture, Market and Trade Economics Division.
30. Casolaro, M. A., Bernaudin, J. F., Saltini, C., Ferrans, V. J., and Crystal, R. G. 1988. Accumulation of Langerhans' cells on the epithelial surface of the lower respiratory tract in normal subjects in association with cigarette smoking. Am. Rev. Respir. Dis. 137, 406-411.
31. Cazzola, M., Bettoncelli, G., Sessa, E., Cricelli, C., and Biscione, G. 2010. Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration80, 112-119.
32. Cazzola, M., Calzetta, L., and Matera, M. G. 2011. beta(2)-adrenoceptor agonists: current and future direction. Br. J. Pharmacol. 163, 4-17.
33. Cazzola, M., Page, C. P., Calzetta, L., and Matera, M. G. 2012. Pharmacology and therapeutics of bronchodilators. Pharmacol. Rev. 64, 450-504.
34. Cazzola, M., Page, C. P., Rogliani, P., and Matera, M. G. 2013. beta2-agonist therapy in lung disease. Am. J. Respir. Crit. Care Med. 187, 690-696.
35. Chang, H. T., Evans, C. T., Weaver, F. M., Burns, S. P., and Parada, J. P. 2005. Etiology and outcomes of veterans with spinal cord injury and disorders hospitalized with community-acquired pneumonia. Arch. Phys. Med. Rehabil. 86, 262-267.
36. Ciofu, O., Mandsberg, L. F., Bjarnsholt, T., Wassermann, T., and Hoiby, N. 2010. Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants. Microbiology156, 1108-1119.
37. Clini, E. M., Beghe, B., and Fabbri, L. M. 2013. Chronic obstructive pulmonary disease is just one component of the complex multimorbidities in patients with COPD. Am. J. Respir. Crit. Care Med. 187, 668-671.
38. Davodeau, F., Peyrat, M. A., Gaschet, J., Hallet, M. M., Triebel, F., Vie, H., Kabelitz, D., and Bonneville, M. 1994. Surface expression of functional T cell receptor chains formed by interlocus recombination on human T lymphocytes. J. Exp. Med. 180, 1685-1691.
39. de Miguel Díez, J., Chancafe Morgan, J., and Jiménez García, R. 2013. The association between COPD and heart failure risk: a review. Int. J. Chron. Obstruct. Pulmon. Dis. 8, 305-312.
40. Decramer, M. and Janssens, W. 2010. Mucoactive therapy in COPD. Eur. Respir. Rev. 19, 134-140.
41. DeVries, C. A. and Ohman, D. E. 1994. Mucoid-to-nonmucoid conversion in alginate-producing Pseudomonas aeruginosa often results from spontaneous mutations in algT, encoding a putative alternate sigma factor, and shows evidence for autoregulation. J. Bacteriol. 176, 6677-6687.
42. Doll, R., Peto, R., Wheatley, K., Gray, R., and Sutherland, I. 1994. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ309, 901-911.
43. Edwards, R. 2004. The problem of tobacco smoking. BMJ328, 217-219.
44. Eisner, M. D., Blanc, P. D., Yelin, E. H., Sidney, S., Katz, P. P., Ackerson, L., Lathon, P., Tolstykh, I., Omachi, T., Byl, N., and Iribarren, C. 2008. COPD as a systemic disease: impact on physical functional limitations. Am. J. Med. 121, 789-796.
45. Espinosa de los Monteros, M. J., Peña, C., Soto Hurtado, E. J., Jareño, J., and Miravitlles, M. 2012. Variability of respiratory symptoms in severe COPD. Arch. Bronconeumol. 48, 3-7.
46. Feghali-Bostwick, C. A., Gadgil, A. S., Otterbein, L. E., Pilewski, J. M., Stoner, M. W., Csizmadia, E., Zhang, Y., Sciurba, F. C., and Duncan, S. R. 2008. Autoantibodies in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 177, 156-163.
47. Ferguson, G. T., Calverley, P. M., Anderson, J. A., Jenkins, C. R., Jones, P. W., Willits, L. R., Yates, J. C., Vestbo, J., and Celli, B. 2009. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest136, 1456-1465.
48. Fishman, A., Martinez, F., Naunheim, K., Piantadosi, S., Wise, R., Ries, A., Weinmann, G., and Wood, D. E. 2003. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N. Engl. J. Med. 348, 2059-2073.
49. Ford, E. S., Mannino, D. M., Zhao, G., Li, C., and Croft, J. B. 2012. Changes in mortality among US adults with COPD in two national cohorts recruited from 1971-1975 and 1988-1994. Chest141, 101-110.
50. Franssen, F. M., Broekhuizen, R., Janssen, P. P., Wouters, E. F., and Schols, A. M. 2005. Limb muscle dysfunction in COPD: effects of muscle wasting and exercise training. Med. Sci. Sports Exerc. 37, 2-9.
51. Friedlander, A. L., Lynch, D., Dyar, L. A., and Bowler, R. P. 2007. Phenotypes of chronic obstructive pulmonary disease. COPD4, 355-384.
52. Gacesa, P. 1988. Alginates. Carbohydr. Polym. 8, 161-182.
53. Garcia-Aymerich, J., Lange, P., Benet, M., Schnohr, P., and Anto, J. M. 2006. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax61, 772-778.
54. Gea, J., Agusti, A., and Roca, J. 2013. Pathophysiology of muscle dysfunction in COPD. J. Appl. Physiol. (1985) 114, 1222-1234.
55. Geppert, T. D. and Lipsky, P. E. 1989. Antigen presentation at the inflammatory site. Crit. Rev. Immunol. 9, 313-362.
56. Giovino, G. A. 2007. The tobacco epidemic in the United States. Am. J. Prev. Med. 33, S318-326.
57. Gosselink, R., Troosters, T., and Decramer, M. 1996. Peripheral muscle weakness contributes to exercise limitation in COPD. Am. J. Respir. Crit. Care Med. 153, 976-980.
58. Graat-Verboom, L., Smeenk, F. W., van den Borne, B. E., Spruit, M. A., Jansen, F. H., van Enschot, J. W., and Wouters, E. F. 2012. Progression of osteoporosis in patients with COPD: a 3-year follow up study. Respir. Med. 106, 861-870.
59. Graat-Verboom, L., van den Borne, B. E., Smeenk, F. W., Spruit, M. A., and Wouters, E. F. 2011. Osteoporosis in COPD outpatients based on bone mineral density and vertebral fractures. J. Bone Miner Res. 26, 561-568.
60. Graat-Verboom, L., Wouters, E. F., Smeenk, F. W., van den Borne, B. E., Lunde, R., and Spruit, M. A. 2009. Current status of research on osteoporosis in COPD: a systematic review. Eur. Respir. J. 34, 209-218.
61. Grossman, Z. 1984. Recognition of self and regulation of specificity at the level of cell populations. Immunol. Rev. 79, 119-138.
62. Gursel, G. and Demirtas, S. 2006. Value of APACHE II, SOFA and CPIS scores in predicting prognosis in patients with ventilator-associated pneumonia. Respiration73, 503-508.
63. Halbert, R. J., Natoli, J. L., Gano, A., Badamgarav, E., Buist, A. S., and Mannino, D. M. 2006. Global burden of COPD: systematic review and meta-analysis. Eur. Respir. J. 28, 523-532.
64. + Th17 type cells associated with chronic cigarette smoke induced airspace enlargement. Immunol. Lett. 121, 13-21.
65. Hassett, D. J. 1996. Anaerobic production of alginate by Pseudomonas aeruginosa: alginate restricts diffusion of oxygen. J. Bacteriol. 178, 7322-7325.
66. Hassett, D. J., Korfhagen, T. R., Irvin, R. T., Schurr, M. J., Sauer, K., Lau, G. W., Sutton, M. D., Yu, H., and Hoiby, N. 2010. Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies. Expert. Opin. Ther. Targets14, 117-130.
67. Hassett, D. J., Woodruff, W. A., Wozniak, D. J., Vasil, M. L., Cohen, M. S., and Ohman, D. E. 1993. Cloning of the sodA and sodB genes encoding manganese and iron superoxide dismutase in Pseudomonas aeruginosa: demonstration of increased manganese superoxide dismutase activity in alginate-producing bacteria. J. Bacteriol. 175, 7658-7665.
68. Hellstrom, K., Vahlberg, B., Urell, C., and Emtner, M. 2009. Fear of falling, fall-related self-efficacy, anxiety and depression in individuals with chronic obstructive pulmonary disease. Clin. Rehabil. 23, 1136-1144.
69. Hill, K., Geist, R., Goldstein, R. S., and Lacasse, Y. 2008. Anxiety and depression in end-stage COPD. Eur. Respir. J. 31, 667-677.
70. Huertas, A. and Palange, P. 2011. COPD: a multifactorial systemic disease. Ther. Adv. Respir. Dis. 5, 217-224.
71. Hurst, J. R., Vestbo, J., Anzueto, A., Locantore, N., Mullerova, H., Tal-Singer, R., Miller, B., Lomas, D. A., Agusti, A., Macnee, W., andet al. 2010. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 363, 1128-1138.
72. Jansen, D. F., Schouten, J. P., Vonk, J. M., Rijcken, B., Timens, W., Kraan, J., Weiss, S. T., and Postma, D. S. 1999. Smoking and airway hyperresponsiveness especially in the presence of blood eosinophilia increase the risk to develop respiratory symptoms: a 25-year follow-up study in the general adult population. Am. J. Respir. Crit. Care Med. 160, 259-264.
73. Janson, C., Marks, G., Buist, S., Gnatiuc, L., Gislason, T., McBurnie, M. A., Nielsen, R., Studnicka, M., Toelle, B., Benediktsdottir, B., andet al. 2013. The impact of COPD on health status: findings from the BOLD study. Eur. Respir. J. 42, 1472-1483.
74. Janssens, L., Brumagne, S., McConnell, A. K., Claeys, K., Pijnenburg, M., Burtin, C., Janssens, W., Decramer, M., and Troosters, T. 2013. Proprioceptive changes impair balance control in individuals with chronic obstructive pulmonary disease. PLoS One8, e57949.
75. Jorgensen, N. R., Schwarz, P., Holme, I., Henriksen, B. M., Petersen, L. J., and Backer, V. 2007. The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir. Med. 101, 177-185.
76. Karayama, M., Inui, N., Suda, T., Nakamura, Y., Nakamura, H., and Chida, K. 2010. Antiendothelial cell antibodies in patients With COPD. Chest138, 1303-1308.
77. Kim, H. C., Mofarrahi, M., and Hussain, S. N. 2008. Skeletal muscle dysfunction in patients with chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 3, 637-658.
78. Kirkham, P. A., Caramori, G., Casolari, P., Papi, A. A., Edwards, M., Shamji, B., Triantaphyllopoulos, K., Hussain, F., Pinart, M., Khan, Y., andet al. 2011. Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 184, 796-802.
79. Kocks, J. W., Asijee, G. M., Tsiligianni, I. G., Kerstjens, H. A., and van der Molen, T. 2011. Functional status measurement in COPD: a review of available methods and their feasibility in primary care. Prim. Care Respir. J. 20, 269-275.
80. Kornmann, O., Beeh, K. M., Beier, J., Geis, U. P., Ksoll, M., and Buhl, R. 2003. Newly diagnosed chronic obstructive pulmonary disease. Clinical features and distribution of the novel stages of the Global Initiative for Obstructive Lung Disease. Respiration70, 67-75.
81. Lacasse, Y., Goldstein, R., Lasserson, T. J., and Martin, S. 2006. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. CD003793.
82. Larsen, M. V., Janner, J. H., Nielsen, S. D., Friis-Moller, A., Ringbaek, T., and Lange, P. 2009. Bacteriology in acute exacerbation of chronic obstructive pulmonary disease in patients admitted to hospital. Scand. J. Infect. Dis. 41, 26-32.
83. Lee, S. H., Goswami, S., Grudo, A., Song, L. Z., Bandi, V., Goodnight-White, S., Green, L., Hacken-Bitar, J., Huh, J., Bakaeen, F., andet al. 2007. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat. Med. 13, 567-569.
84. Lehouck, A., Boonen, S., Decramer, M., and Janssens, W. 2011. COPD, bone metabolism, and osteoporosis. Chest139, 648-657.
85. Macchia, A., Rodriguez Moncalvo, J. J., Kleinert, M., Comignani, P. D., Gimeno, G., Arakaki, D., Laffaye, N., Fuselli, J. J., Massolin, H. P., Gambarte, J., andet al. 2012. Unrecognised ventricular dysfunction in COPD. Eur. Respir J. 39, 51-58.
86. MacNee, W. 2013. Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. Ann. Med. 45, 291-300.
87. Major, T. A., Panmanee, W., Mortensen, J. E., Gray, L. D., Hoglen, N., and Hassett, D. J. 2010. Sodium nitrite-mediated killing of the major cystic fibrosis pathogens Pseudomonas aeruginosa, Staphylococcus aureus, and Burkholderia cepacia under anaerobic planktonic and biofilm conditions. Antimicrob. Agents Chemother. 54, 4671-4677.
88. Majumdar, S. R., Villa-Roel, C., Lyons, K. J., and Rowe, B. H. 2010. Prevalence and predictors of vertebral fracture in patients with chronic obstructive pulmonary disease. Respir. Med. 104, 260-266.
89. Make, B., Krachman, S., Panos, R. J., Doherty, D. E., and Stoller, J. K. 2010. Oxygen therapy in advanced COPD: in whom does it work? Semin. Respir. Crit. Care Med. 31, 334-342.
90. Mammen, M. J. and Sethi, S. 2012. Macrolide therapy for the prevention of acute exacerbations in chronic obstructive pulmonary disease. Pol. Arch. Med. Wewn. 122, 54-59.
91. Mannino, D. M., Gagnon, R. C., Petty, T. L., and Lydick, E. 2000. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch. Intern. Med. 160, 1683-1689.
92. Mariolis, P., Rock, V., Asman, K., Merritt, M., Malarcher, A., Husten, C., and Pechacek, C. 2006. Tobacco use among adults - United States, 2005. Morbidity and Mortality Weekly Report. CDC, Dept. of Health and Human Services.
93. Martínez-García, M. A., de la Rosa, C. D., Soler-Cataluña, J. J., 'Donat-Sanz, Y., Serra, P. C., Lerma, M. A., Ballestín, J., Sánchez, I. V., Selma Ferrer, M. J., Dalfo, A. R., andet al. 2013. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 187, 823-831.
94. Martin, D. W., Schurr, M. J., Mudd, M. H., Govan, J. R., Holloway, B. W., and Deretic, V. 1993. Mechanism of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients. Proc. Natl. Acad. Sci. USA90, 8377-8381.
95. Martinez-Solano, L., Macia, M. D., Fajardo, A., Oliver, A., and Martinez, J. L. 2008. Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. Clin. Infect. Dis. 47, 1526-1533.
96. Martinez, F. J., Curtis, J. L., and Albert, R. 2008. Role of macrolide therapy in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 3, 331-350.
97. Mathers, C. D. and Loncar, D. 2006. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3, e442.
98. McEvoy, C. E., Ensrud, K. E., Bender, E., Genant, H. K., Yu, W., Griffith, J. M., and Niewoehner, D. E. 1998. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am. J. Respir. Crit Care Med. 157, 704-709.
99. Miravitlles, M. 2011. Cough and sputum production as risk factors for poor outcomes in patients with COPD. Respir. Med. 105, 1118-1128.
100. Mohsen, A. H., Peck, R. J., Mason, Z., Mattock, L., and McKendrick, M. W. 2001. Lung function tests and risk factors for pneumonia in adults with chickenpox. Thorax56, 796-799.
101. Mokdad, A. H., Marks, J. S., Stroup, D. F., and Gerberding, J. L. 2004. Actual causes of death in the United States, 2000. JAMA291, 1238-1245.
102. Montero, M., Dominguez, M., Orozco-Levi, M., Salvado, M., and Knobel, H. 2009. Mortality of COPD patients infected with multi-resistant Pseudomonas aeruginosa: a case and control study. Infection37, 16-19.
103. Motz, G. T., Eppert, B. L., Sun, G., Wesselkamper, S. C., Linke, M. J., Deka, R., and Borchers, M. T. 2008. Persistence of lung CD8 T cell oligoclonal expansions upon smoking cessation in a mouse model of cigarette smoke-induced emphysema. J. Immunol. 181, 8036-8043.
104. Motz, G. T., Eppert, B. L., Wortham, B. W., Amos-Kroohs, R. M., Flury, J. L., Wesselkamper, S. C., and Borchers, M. T. 2010. Chronic cigarette smoke exposure primes NK cell activation in a mouse model of chronic obstructive pulmonary disease. J. Immunol. 184, 4460-4469.
105. Mullerova, H., Agusti, A., Erqou, S., and Mapel, D. W. 2013. Cardiovascular comorbidity in COPD: systematic literature review. Chest144, 1163-1178.
106. Murphy, T. F., Brauer, A. L., Eschberger, K., Lobbins, P., Grove, L., Cai, X., and Sethi, S. 2008. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 177, 853-860.
107. Nunez, B., Sauleda, J., Anto, J. M., Julia, M. R., Orozco, M., Monso, E., Noguera, A., Gomez, F. P., Garcia-Aymerich, J., and Agusti, A. 2011. Anti-tissue antibodies are related to lung function in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 183, 1025-1031.
108. Nuorti, J. P., Butler, J. C., Farley, M. M., Harrison, L. H., McGeer, A., Kolczak, M. S., and Breiman, R. F. 2000. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N. Engl. J. Med. 342, 681-689.
109. Nussbaumer-Ochsner, Y. and Rabe, K. F. 2011. Systemic manifestations of COPD. Chest139, 165-173.
110. Nuti, R., Siviero, P., Maggi, S., Guglielmi, G., Caffarelli, C., Crepaldi, G., and Gonnelli, S. 2009. Vertebral fractures in patients with chronic obstructive pulmonary disease: the EOLO study. Osteoporos. Int. 20, 989-998.
111. O'Donnell, D. E. and Parker, C. M. 2006. COPD exacerbations. 3: Pathophysiology. Thorax61, 354-361.
112. Ozalevli, S., Ilgin, D., Narin, S., and Akkoclu, A. 2011. Association between disease-related factors and balance and falls among the elderly with COPD: a cross-sectional study. Aging Clin. Exp. Res. 23, 372-377.
113. Panos, R. J. and Eschenbacher, W. 2009. Exertional desaturation in patients with chronic obstructive pulmonary disease. COPD6, 478-487.
114. Papaioannou, A., Parkinson, W., Ferko, N., Probyn, L., Ioannidis, G., Jurriaans, E., Cox, G., Cook, R. J., Kumbhare, D., and Adachi, J. D. 2003. Prevalence of vertebral fractures among patients with chronic obstructive pulmonary disease in Canada. Osteoporos. Int. 14, 913-917.
115. Parameswaran, G. I. and Sethi, S. 2012. Pseudomonas infection in chronic obstructive pulmonary disease. Future Microbiol. 7, 1129-1132.
116. Pastor, P., Medley, F., and Murphy, T. V. 1998. Invasive pneumococcal disease in Dallas County, Texas: results from population-based surveillance in 1995. Clin. Infect. Dis. 26, 590-595.
117. Pitta, F., Troosters, T., Probst, V. S., Spruit, M. A., Decramer, M., and Gosselink, R. 2006. Physical activity and hospitalization for exacerbation of COPD. Chest129, 536-544.
118. Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R., van Weel, C., andet al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 176, 532-555.
119. Reid, D. J. and Pham, N. T. 2012. Roflumilast: a novel treatment for chronic obstructive pulmonary disease. Ann. Pharmacother. 46, 521-529.
120. Ries, A. L. 2008. Pulmonary rehabilitation: summary of an evidence-based guideline. Respir. Care53, 1203-1207.
121. Rittayamai, N., Chuaychoo, B., and Sriwijitkamol, A. 2012. Prevalence of osteoporosis and osteopenia in Thai COPD patients. J. Med. Assoc. Thai95, 1021-1027.
122. Roche, N. 2007. Characteristics of obstructive respiratory diseases (asthma and COPD) in the elderly. Rev. Mal. Respir. 24, 803-805.
123. Roig, M., Eng, J. J., MacIntyre, D. L., Road, J. D., FitzGerald, J. M., Burns, J., and Reid, W. D. 2011. Falls in people with chronic obstructive pulmonary disease: an observational cohort study. Respir. Med. 105, 461-469.
124. Rosell, A., Monso, E., Soler, N., Torres, F., Angrill, J., Riise, G., Zalacain, R., Morera, J., and Torres, A. 2005. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch. Intern. Med. 165, 891-897.
125. Russell, R. E., Thorley, A., Culpitt, S. V., Dodd, S., Donnelly, L. E., Demattos, C., Fitzgerald, M., and Barnes, P. J. 2002. Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am. J. Physiol. Lung Cell Mol. Physiol. 283, L867-873.
126. Saetta, M., Di Stefano, A., Maestrelli, P., Ferraresso, A., Drigo, R., Potena, A., Ciaccia, A., and Fabbri, L. M. 1993. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am. Rev. Respir. Dis. 147, 301-306.
127. Schnell, K., Weiss, C. O., Lee, T., Krishnan, J. A., Leff, B., Wolff, J. L., and Boyd, C. 2012. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008. BMC Pulm. Med. 12, 26.
128. Sciurba, F. C., Ernst, A., Herth, F. J., Strange, C., Criner, G. J., Marquette, C. H., Kovitz, K. L., Chiacchierini, R. P., Goldin, J., and McLennan, G. 2010. A randomized study of endobronchial valves for advanced emphysema. N. Engl. J. Med. 363, 1233-1244.
129. Seaman, J., Leonard, A. C., and Panos, R. J. 2010. Health care utilization history, GOLD guidelines, and respiratory medication prescriptions in patients with COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 5, 89-97.
130. Seemungal, T. A., Wilkinson, T. M., Hurst, J. R., Perera, W. R., Sapsford, R. J., and Wedzicha, J. A. 2008. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am. J. Respir. Crit. Care Med. 178, 1139-1147.
131. Shan, M., Cheng, H. F., Song, L. Z., Roberts, L., Green, L., Hacken-Bitar, J., Huh, J., Bakaeen, F., Coxson, H. O., Storness-Bliss, C., andet al. 2009. Lung myeloid dendritic cells coordinately induce TH1 and TH17 responses in human emphysema. Sci. Transl. Med. 1, 4ra10.
132. Shan, M., Yuan, X., Song, L. Z., Roberts, L., Zarinkamar, N., Seryshev, A., Zhang, Y., Hilsenbeck, S., Chang, S. H., Dong, C., Corry, D. B., and Kheradmand, F. 2012. Cigarette smoke induction of osteopontin (SPP1) mediates T(H)17 inflammation in human and experimental emphysema. Sci. Transl. Med. 4, 117ra119.
133. Sherrill, D. L., Lebowitz, M. D., Knudson, R. J., and Burrows, B. 1991. Smoking and symptom effects on the curves of lung function growth and decline. Am. Rev. Respir. Dis. 144, 17-22.
134. Simpson, J. A., Smith, S. E., and Dean, R. T. 1989. Scavenging by alginate of free radicals released by macrophages. Free Rad. Biol. Med. 6, 347-353.
135. Smith, M. D., Chang, A. T., Seale, H. E., Walsh, J. R., and Hodges, P. W. 2010. Balance is impaired in people with chronic obstructive pulmonary disease. Gait. Posture31, 456-460.
136. Soler, P., Moreau, A., Basset, F., and Hance, A. J. 1989. Cigarette smoking-induced changes in the number and differentiated state of pulmonary dendritic cells/Langerhans cells. Am. Rev. Respir. Dis. 139, 1112-1117.
137. Stampfli, M. R. and Anderson, G. P. 2009. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat. Rev. Immunol. 9, 377-384.
138. Stav, D. and Raz, M. 2009. Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study. Chest136, 381-386.
139. Stoller, J. K., Panos, R. J., Krachman, S., Doherty, D. E., and Make, B. 2010. Oxygen therapy for patients with COPD: current evidence and the long-term oxygen treatment trial. Chest138, 179-187.
140. Su, S. and Hassett, D. J. 2012. Anaerobic Pseudomonas aeruginosa and other obligately anaerobic bacterial biofilms growing in the thick airway mucus of chronically infected cystic fibrosis patients: an emerging paradigm or "Old Hat"? Expert Opin. Ther. Targets16, 859-873.
141. Sullivan, A. K., Simonian, P. L., Falta, M. T., Mitchell, J. D., Cosgrove, G. P., Brown, K. K., Kotzin, B. L., Voelkel, N. F., and Fontenot, A. P. 2005. Oligoclonal CD4+ T cells in the lungs of patients with severe emphysema. Am. J. Respir. Crit. Care Med. 172, 590-596.
142. Tager, I. B., Segal, M. R., Speizer, F. E., and Weiss, S. T. 1988. The natural history of forced expiratory volumes. Effect of cigarette smoking and respiratory symptoms. Am. Rev. Respir Dis. 138, 837-849.
143. Tashkin, D. P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S., and Decramer, M. 2008. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 359, 1543-1554.
144. Tidwell, S. L., Westfall, E., and Dransfield, M. T. 2012. Lung volume reduction for advanced emphysema: surgical and bronchoscopic approaches. South Med. J. 105, 56-61.
145. Tobin, M. J., Laghi, F., and Brochard, L. 2009. Role of the respiratory muscles in acute respiratory failure of COPD: lessons from weaning failure. J. Appl. Physiol. (1985)107, 962-970.
146. Tockman, M. S., Anthonisen, N. R., Wright, E. C., and Donithan, M. G. 1987. Airways obstruction and the risk for lung cancer. Ann. Intern. Med. 106, 512-518.
147. Tonnesen, P. 2013. Smoking cessation and COPD. Eur. Respir. Rev. 22, 37-43.
148. Vandivier, R. W., Henson, P. M., and Douglas, I. S. 2006. Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest129, 1673-1682.
149. Varkey, J. B., Varkey, A. B., and Varkey, B. 2009. Prophylactic vaccinations in chronic obstructive pulmonary disease: current status. Curr. Opin. Pulm. Med. 15, 90-99.
150. Vijayan, V. K. 2013. Chronic obstructive pulmonary disease. Indian J. Med. Res. 137, 251-269.
151. Wallace, W. A., Gillooly, M., and Lamb, D. 1992. Intra-alveolar macrophage numbers in current smokers and non-smokers: a morphometric study of tissue sections. Thorax47, 437-440.
152. Walters, J. A., Smith, S., Poole, P., Granger, R. H., and Wood-Baker, R. 2010. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. CD001390.
153. Wang, J., Nie, B., Xiong, W., and Xu, Y. 2012. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis. J. Clin. Pharm. Ther. 37, 204-211.
154. Wasswa-Kintu, S., Gan, W. Q., Man, S. F., Pare, P. D., and Sin, D. D. 2005. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax60, 570-575.
155. Wedzicha, J. A., Brill, S. E., Allinson, J. P., and Donaldson, G. C. 2013. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 11, 181.
156. Wedzicha, J. A. and Seemungal, T. A. 2007. COPD exacerbations: defining their cause and prevention. Lancet370, 786-796.
157. Witek, T. J. Jr. and Mahler, D. A. 2003. Minimal important differ ence of the transition dyspnoea index in a multinational clinical trial. Eur. Respir. J. 21, 267-272.
158. Woodruff, P. G., Koth, L. L., Yang, Y. H., Rodriguez, M. W., Favoreto, S., Dolganov, G. M., Paquet, A. C., and Erle, D. J. 2005. A distinctive alveolar macrophage activation state induced by cigarette smoking. Am. J. Respir Crit. Care Med. 172, 1383-1392.
159. Worlitzsch, D., Tarran, R., Ulrich, M., Schwab, U., Cekici, A., Meyer, K. C., Birrer, P., Bellon, G., Berger, J., Wei, T., andet al. 2002. Reduced oxygen concentrations in airway mucus contribute to the early and late pathogenesis of Pseudomonas aeruginosa cystic fibrosis airway infection. J. Clin. Invest. 109, 317-325.
160. Wortham, B. W., Eppert, B. L., Motz, G. T., Flury, J. L., Orozco-Levi, M., Hoebe, K., Panos, R. J., Maxfield, M., Glasser, S. W., Senft, A. P., andet al. 2012. NKG2D mediates NK cell hyperresponsiveness and influenza-induced pathologies in a mouse model of chronic obstructive pulmonary disease. J. Immunol. 188, 4468-4475.
161. Wyckoff, T. J., Thomas, B., Hassett, D. J., and Wozniak, D. J. 2002. Static growth of mucoid Pseudomonas aeruginosa selects for non-mucoid variants that have acquired flagellum-dependent motility. Microbiology148, 3423-3430.
162. Xu, M., Scott, J. E., Liu, K. Z., Bishop, H. R., Renaud, D. E., Palmer, R. M., Soussi-Gounni, A., and Scott, D. A. 2008. The influence of nicotine on granulocytic differentiation - inhibition of the oxidative burst and bacterial killing and increased matrix metalloproteinase-9 release. BMC Cell Biol. 9, 19.
163. Yohannes, A. M., Connolly, M. J., and Hanania, N. A. 2013. Ten years of tiotropium: clinical impact and patient perspectives. Int. J. Chron. Obstruct. Pulmon. Dis. 8, 117-125.
164. Yoon, S. S., Coakley, R., Lau, G. W., Lymar, S. V., Gaston, B., Karabulut, A. C., Hennigan, R. F., Hwang, S. H., Buettner, G., Schurr, M. J., andet al. 2006. Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions. J. Clin. Invest. 116, 436-446.
165. Yoon, S. S., Hennigan, R. F., Hilliard, G. M., Ochsner, U. A., Parvatiyar, K., Kamani, M. C., Allen, H. L., DeKievit, T. R., Gardner, P. R., Schwab, U., andet al. 2002. Pseudomonas aeruginosa anaerobic respiration in biofilms: Relationships to cystic fibrosis pathogenesis. Dev. Cell3, 593-603.